1. Clinical pharmacokinetics and pharmacodynamics of afatinib;Wind;Clin. Pharmacokinet.,2017
2. Population pharmacokinetics of afatinib and exposure-safety relationships in Japanese patients with EGFR mutation-positive non-small cell lung cancer;Nakao;Sci. Rep.,2019
3. Nanocarrier centered therapeutic approaches: recent developments with insight towards the future in the management of lung cancer;Vanza;J. Drug Deliv. Sci. Technol.,2020
4. DOE supported optimization of biodegradable polymeric nanoparticles based dry powder inhaler for targeted delivery of afatinib in non-small cell lung cancer;Vanza;J. Drug Deliv. Sci. Technol.,2023